for diabetic neuropathy, a common protocol is daily IV infusions for 2-4 weeks as an initial therapy
It gained its first FDA approval in 2021, but most recently the indication was approved to reduce the risk of heart attack and stroke in obese or overweight adults with cardiovascular disease
Research on 5-Amino-1MQ is still emerging, but preclinical studies suggest it has a good safety profile when used properly
doi: 10.1053/j.gastro.2015.06.045 34 TortiSVManzDHPaulBTBlanchette-FarraNTortiFM
Additionally, certain peptide sequences may be recognized as foreign by the immune system, increasing the likelihood of unwanted immune reactions
In terms of safety outcomes, the analysis indicated a significantly higher risk of gastrointestinal adverse events, including diarrhea (RR = 1.75, 95% CI 1.10